• Wells Fargo upgraded Cardinal Health (NYSE:CAH) to "Overweight" with a price target increase from $237 to $256.
• Q2 2026 results showcased a 19% revenue increase to $66 billion and a 36% rise in non-GAAP EPS to $2.63.
• Cardinal Health raised its FY 2026 EPS guidance to $10.15 - $10.35, indicating a 23-26% year-over-year growth.

Cardinal Health (NYSE:CAH) is a prominent player in the healthcare sector, providing pharmaceuticals and medical products to over 100,000 locations daily. The company is a key infrastructure provider in the U.S. healthcare system, focusing on high-margin specialty services and clinical products. Cardinal Health competes with other major distributors like McKesson and AmerisourceBergen.

On February 10, 2026, Wells Fargo adjusted its rating for Cardinal Health to "Overweight," indicating a positive outlook on the stock. At the time, CAH was priced at $225.76. Wells Fargo also raised its price target from $237 to $256, suggesting confidence in the company's future performance.

Cardinal Health's Q2 2026 results exceeded expectations, leading to a significant surge in its stock price. The company reported a 19% increase in revenue, reaching $66 billion, and a 36% rise in non-GAAP EPS to $2.63. This growth was driven by strong pharmaceutical demand, highlighting the company's robust operational performance.

The company raised its fiscal year 2026 outlook for the second time in a month, projecting EPS guidance between $10.15 and $10.35. This indicates a year-over-year growth of 23-26%. All five operating segments achieved double-digit profit growth, with the Pharmaceutical and Specialty Solutions segment leading with a 29% increase.

Sales of GLP-1 medications contributed approximately 6 percentage points to the revenue growth in the Pharmaceutical and Specialty Solutions segment. Additionally, the BioPharma Solutions segment experienced over 30% revenue growth. This performance underscores Cardinal Health's successful shift towards high-margin specialty services and clinical products.